— Published date: 6/2/2026
Value Proposition: First-in-class antisense oligonucleotide (ASO) therapy selectively lowering ACOX1 to enable disease-modifying treatment of Mitchell Syndrome and unlocking a metabolic shift facilitating weight loss.
Technology Description: Mitchell Syndrome is an u…
— Value Proposition: This invention uses a novel gene therapy that blocks the axon degeneration typical of neurodegenerative diseases.
Technology Description
Researchers at Washington University in St. Louis have developed a new strategy for treatment of neurodegenerative diseases with axonopathy.…
— Published date: 1/14/2026
Value Proposition: Entry receptors that bind directly to TBEV, promoting virus attachment to treat TBEV and other viruses.
Technology Description
Researchers at Washington University in St. Louis have developed LRP8 soluble decoy receptors (minimal domains-Fc fusion …
— Published date: 1/14/2026
Value Proposition: Soluble engineered decoy receptor protein that on its own can be used to treat multiple alphavirus types.
Technology Description
Researchers at Washington University in St. Louis have developed a composition of matter that consists of a mutagenized…
— Published date: 1/14/2026
Value Proposition: First antiviral treatment that uses soluble receptors to treat yellow fever.
Technology Description
Researchers at Washington University in St. Louis have developed new soluble receptor decoy Fc-fusion protein inhibitors for the treatment of yellow f…
| Name | # Summaries | Author | Action |
|---|---|---|---|
| 15 | |||
| 13 | |||
| 1 | |||
| 15 | |||
| 26 | |||
| 14 | |||
| 14 |
Creating...
